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Abstract
Introduction: This study examined the association of spirometry-defined airflow obstruction and 
self-reported COPD defined as self-reported doctor diagnosed chronic bronchitis or emphysema, 
with occupational exposure among ever-employed US adults.
Methods: Data were obtained from the National Health and Nutrition Examination Survey 
(NHANES) 2007–2008 to 2011–2012, a nationally representative study of the non-
institutionalized civilian US population. Reported current and/or longest held job were used to 
create prevalence estimates and prevalence odds ratios (PORs) (adjusted for age, gender, race, and 
smoking status) for airflow obstruction and self-reported COPD by occupational exposure, 
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determined using both NHANES participants’ selfreported exposures and eight categories of 
COPD job exposure matrix (JEM) assigned exposures.
Results: Significant PORs for airflow obstruction and self-reported COPD respectively were 
observed with self-reported exposure for ≥20 years to mineral dust (POR = 1.44; 95% confidence 
interval (CI) 1.13–1.85; POR = 1.69; 95% CI 1.17–2.43) and exhaust fumes (POR = 1.65; 95% CI 
1.27–2.15; POR = 2.22; 95% CI 1.37–3.58). Airflow obstruction or self-reported` COPD were 
also associated with COPD-JEM assigned high exposure to mineral dust, combined dust, diesel 
exhaust, vapor-gas, sensitizers, and overall exposure.
Conclusion: Airflow obstruction and self-reported COPD are associated with both self-reported 
and JEM-assigned exposures.
Keywords
airflow obstruction; CDC; COPD; job exposure matrix; NHANES; occupational exposure; 
prevalence
1 | INTRODUCTION
Occupational exposure to vapors, gases, dusts, and fumes is causally associated with 
increased levels of obstructive lung function impairment and increased prevalence of chronic 
bronchitis.1–3 Although tobacco smoking is the primary risk factor for chronic obstructive 
pulmonary disease (COPD), a recent American Thoracic Society (ATS) statement, based on 
a review of the literature, concluded that occupational exposures are causally related to 
development of COPD and that the occupational attribution to COPD is over 15%.4
An understanding of workers’ occupational exposures can be captured through several 
different methods. One method is to obtain self-reported exposures through an interview or 
questionnaire administered to study participants.5 Self-reported exposures can be linked to 
respiratory health outcomes in epidemiologic studies. However, self-reports of occupational 
exposure may be subject to various biases (eg, recall bias or interviewer bias). Using a job 
exposure matrix (JEM) can reduce or eliminate the individual’s recall bias through assigning 
exposure levels based on occupation.
Blanc et al6 developed a JEM for COPD and found associations between COPD and the 
overall exposure category including vapor-gas, dust, and fumes.7 Some more recent studies 
on COPD and occupational exposure using another instrument, the ALOHA JEM, found 
that occupational exposure to pesticides was associated with airflow obstruction8 while the 
European Community Respiratory Health Survey found occupational exposures to 
biological dusts, gases and fumes, and pesticides were associated with the 20 year incidence 
of COPD.9 In addition, one United Kingdom study assessed COPD and found associations 
between both self-reported and JEM-associated exposures to vapors, gas, dust, and fumes.10 
Another United Kingdom study reported that occupational exposure in coal mining, factory 
work, work with solvents, and welding and shipyard work were predictors of respiratory 
symptoms.11
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The National Institute for Occupational Safety and Health (NIOSH) developed a JEM for 
COPD that has separate exposure categories for vapor-gas, dust, and fumes in addition to an 
independently assigned overall vapor-gas, dust, and fumes exposure category. This COPD-
JEM has been applied to occupational data collected from population-specific studies and 
found to be a useful tool for measuring the attribution of spirometry-defined COPD with 
occupational exposure.12,13 NIOSH recently expanded the COPD-JEM to include diesel 
exhaust fumes and sensitizers.
The purpose of the present study was to examine, in a nationally representative sample, the 
association of spirometry-defined airflow obstruction and self-reported COPD with multiple 
measures of occupational exposures. This study is novel because detailed four-digit 
occupation codes for each NHANES study participant were matched with detailed 
occupation codes using the NIOSH COPD-JEM. Occupational exposures were determined 
by: (i) NHANES self-reported occupational exposure data and (ii) application of the NIOSH 
COPD-JEM to NHANES data on self-reported, longest-held occupation.
2 | METHODS
2.1 | Study design and population
The NHANES is a continuous, cross-sectional survey conducted by the National Center for 
Health Statistics. A complex, multistage probability sampling design is used to generate a 
representative sample of the civilian, non-institutionalized US population.14,15 Participants 
receive a detailed in-home interview followed by a physical examination at a mobile 
examination center. Data are collected continuously, but released in 2-year cycles. Data from 
three 2-year cycles were included in the analysis: 2007–2008, 2009–2010, and 2011–2012. 
The examination response rate for each cycle was 75.4%, 77.3%, and 69.5%, respectively.16 
These cycles contain the most current NHANES data on respondent’s longest held job, 
occupational exposures, and spirometry.
The sample for the analysis of airflow obstruction included ever-employed NHANES 
respondents aged 18–79 years with valid pre-bronchodilator spirometry and height data (n = 
13 044). The sample for the analysis of self-reported COPD included ever-employed 
NHANES respondents aged 20–79 years (n = 15 777). There is overlap between the samples 
because both included those aged 20–79 years that were interviewed and who received a 
physical examination. The analytic sample for self-reported COPD includes more 
participants because it is not limited to people with valid spirometry.
2.2 | Variable definitions
Respondents 18–19 years of age were asked different smoking questions than respondents 
20–79 years of age. A history of tobacco or nicotine products use was used to identify 
“never smokers” including those 18–19 years of age who did not use tobacco or nicotine 
products (including cigarettes) in the last 5 days; and those 20–79 years who smoked <100 
cigarettes during their entire life. “Ever smokers” included those 18–19 years of age who 
used tobacco or nicotine products (including cigarettes) in the last five days and those 20–79 
years who smoked at least 100 cigarettes during their entire life.
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Respiratory health outcomes were established by questionnaire responses for participants 
20–79 years and spirometry data. Participants were determined to have self-reported COPD 
if they reported that a doctor or other health professional had ever told them that they had 
chronic bronchitis and they still had chronic bronchitis, or a doctor or other health 
professional had ever told them that they had emphysema. For more details on the NHANES 
variables analyzed, see documentation of NHANES.14
Spirometry details for the 2007–2008 to 2011–2012 NHANES are discussed elsewhere.5,17 
Airflow obstruction was defined per the ATS/European Respiratory Society (ERS) criterion 
as the ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/
FVC) <lower limit of normal (LLN) (ie, the lower 5th percentile).18 Normative reference 
equations developed from NHANES III data were used to determine the predicted and LLN 
pulmonary function values.19 Post-bronchodilator spirometry was performed as a part of the 
NHANES study. However only a limited number of NHANES participants selected for post-
bronchodilator spirometry actually performed it.
For this study, self-reported longest held occupation for ever-employed participants (both 
currently working and no longer working) was used. Longest held occupation was 
determined from the NHANES question, “Thinking of all the paid jobs or businesses you 
ever had, what kind of work were you doing the longest?” If the participant reported the kind 
of work they were doing the longest was the same as their current, then current occupation 
was used as the longest held.14 Workers reporting their longest held occupation was “Armed 
forces” were included. We excluded from our analysis participants not reporting a longest 
held occupation, such as participants who had never worked. NIOSH’s Division of 
Surveillance, Hazard Evaluations, and Field Studies generated four-digit occupation codes 
for respondents’ current and/or longest held job using the US Census Bureau’s 2002 version 
of its Occupation and Industry coding system.20 The coding procedures remained the same 
across all three cycles. These restricted data were accessed via the National Center for Heath 
Statistics’ Research Data Center (https://www.cdc.gov/rdc/b1datatype/dt100.htm).
2.3 | Occupational exposure
2.3.1 | Self-reported—NHANES participants were asked about exposures to specific 
substances in the workplace. Those responding “yes” for questions about work exposure to 
mineral dust (“dust from rock, sand, concrete, coal, asbestos, silica or soil”), organic dust 
(“dust from flours, grains, wood, cotton, plants or animals”), exhaust fumes (“exhaust fumes 
from trucks, buses, heavy machinery or diesel engines”), or other gases, vapors or fumes 
(“vapors from paints, cleaning products, glues, solvents, and acids; or welding/soldering 
fumes”) in any of their jobs were considered to have self-reported exposure to the respective 
substances. They were then asked to report the number of years they had been exposed to the 
respective substance. We grouped self-reported years of exposure into categories (no 
exposure, >0–9 years, 10–19 years, ≥20 years of exposure) for each substance. Participants 
reporting “yes” to any of the above occupational exposure questions were also considered to 
have “ever dust and/or fume” exposure.
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2.4 | COPD-JEM assigned
A NIOSH COPD-JEM was previously constructed by three NIOSH industrial hygienists and 
was based on the principles of the Blanc et al COPD-JEM.7 The Blanc COPD-JEM 
contained one overall vapor-gas, dust, and fumes exposure category. The NIOSH COPD-
JEM12,13 was developed to be a generalizable tool to assess COPD risk by assigning 
exposure levels (low exposure, medium exposure, or high exposure) to all the US Census 
Bureau’s 2002 occupations.20 The low exposure level included no exposure and low 
exposure to vapor-gas, dust, and fumes. For each self-reported, longest held NHANES 
occupation, NIOSH COPD-JEM exposure levels (representing the likelihood of the presence 
and severity of occupational exposure) were assigned for eight COPD-related occupational 
exposure categories. The occupational exposure categories applied in this study included 
mineral dust, organic dust, combined dust, diesel exhaust fumes, vapor-gas, sensitizers, and 
fumes, in addition to an overall COPD-related occupational exposure category. The 
combined dust category takes into consideration both organic dust and mineral dust (plus 
metal dust) and uses the highest exposure level of either the organic dust or the mineral dust 
exposure level. Sensitizers included respiratory hazards associated with COPD such as 
welding operations, glues, isocyanates, and animal dander.21 The overall NIOSH COPD-
JEM occupational exposure level considers the above exposure categories and environmental 
tobacco smoke and assigns one exposure level for each self-reported, longest held NHANES 
occupation.
2.5 | Statistical analysis
Statistical analyses were performed using SAS® 9.4 (SAS Institute Inc., Cary, NC) complex 
survey procedures to adjust for differential probabilities of selection and the complex 
sampling design. Age-standardized prevalence of airflow obstruction and self-reported 
COPD with corresponding 95% confidence intervals (CIs) were calculated using PROC 
SURVEYREG for occupational exposure. For standardization we used the standard age 
distribution of the 2000 US Census Population age structure for age groups 18–39, 40–59, 
and 60–79 years for airflow obstruction and 20–39,40–59, and 60–79 years for self-reported 
COPD.22 NHANES examination sampling weights were used to obtain estimates 
representative of the civilian, non-institutionalized US population for airflow obstruction 
outcomes and interview sampling weights were used to obtain representative estimates for 
self-reported COPD.
Variance estimates were computed using the Taylor series linearization approximation 
method. We calculated relative standard errors (RSE), and identified estimates with an RSE 
greater than 30%, which are potentially unreliable and should be interpreted with caution. 
Estimates with an RSE >36% are not presented.
We used multivariable logistic regression models to calculate prevalence, prevalence odds 
ratios (POR), and 95% CIs for airflow obstruction and self-reported COPD by occupational 
exposure. PORs by occupational exposure were adjusted for age, gender, race/Hispanic 
origin (non-Hispanic white, non-Hispanic black, Mexican American, other Hispanic, and 
other), and cigarette use (ever, never). The reference group for each of the self-reported 
exposures were those that did not report exposure to that substance. The reference group for 
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each JEM-assigned exposure was the low exposure level for that substance. Significant 
exposures were those where the 95% CI did not include 1.0. Adjusted PORs by occupational 
exposure were also calculated for never smokers.
3 | RESULTS
3.1 | Prevalence
The prevalences of airflow obstruction among ever-employed US adults overall, and for 
never smokers and ever smokers by self-reported and COPD-JEM assigned exposures are 
presented in Table 1. The age-standardized prevalence of airflow obstruction was 12.40%. 
The prevalence of airflow obstruction among never smokers was, in general, significantly 
lower than the prevalence among ever smokers.
The prevalences of self-reported COPD among ever-employed US adults overall, and for 
never smokers and ever smokers by self-reported and COPD-JEM assigned exposures are 
presented in Table 2. The age-standardized prevalence of self-reported COPD was 3.47%.
3.2 | Prevalence odds ratios (PORs)
The PORs for airflow obstruction and self-reported COPD, adjusted for age, gender, race, 
and smoking status, by self-reported and COPD-JEM assigned exposures are presented in 
Table 3.
3.3 | Airflow obstruction—self-reported exposure
The PORs for airflow obstruction among those self-reporting ≥20 years of mineral dust 
exposure, organic dust exposure, or exhaust fumes exposure were significantly higher 
compared to each non-exposed reference group (Table 3).
3.4 | Airflow obstruction—COPD-JEM assigned exposure
When compared to the low exposure level in each COPD-JEM occupational exposure 
category, the odds of airflow obstruction among those with high exposure level were 
elevated for mineral dust, combined dust, diesel exhaust, vapor-gas, sensitizers, and overall 
exposure (Table 3). There were no associations with fumes.
A supplement provides age-standardized prevalence and PORs for moderate and more 
severe airflow obstruction by self-reported and JEM-assigned exposures. The results are 
provided in Supplement Table S1.
3.5 | Self-reported COPD—self-reported exposure
The odds of self-reported COPD were elevated for those with self-reported exposure 
compared to those with no exposure in each category of exposure for mineral dust, organic 
dust, exhaust fumes, and other gases/vapors or fumes. Additionally, the years of exposure 
also resulted in elevated odds of self-reported COPD for most categories of exposure (Table 
3). There were also elevated odds of self-reported COPD among never smokers exposed to 
mineral dust (POR = 2.14; 95% CI 1.57–2.91), exhaust fumes (POR = 2.33; 95% CI 1.43–
3.79), and ever dust and/or fumes (POR = 1.35; 95% CI 1.02–1.80) (data not shown).
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3.6 | Self-reported COPD—COPD-JEM assigned exposure
When compared to the low COPD-JEM exposure level in each occupational exposure 
category, the odds of self-reported COPD among those with high exposure level was 
elevated for combined dust, diesel exhaust, vapor-gas, sensitizers, and overall exposure 
(Table 3). Among never smokers the numbers were generally either too small to analyze or 
estimates were unreliable. There were no associations with fumes.
4 | DISCUSSION
This is the first study to examine the association between airflow obstruction, self-reported 
COPD, and occupational exposure using NHANES 2007–2008 to 2011–2012 detailed, four-
digit occupation data and a COPD-JEM. The detailed NHANES occupation data were 
necessary to match with the detailed US Census Bureau’s 2002 occupation codes in the 
NIOSH COPD-JEM. The NIOSH COPD-JEM provided exposure levels representing the 
likelihood of exposures related to COPD for each detailed occupation. Application of this 
COPD-JEM to recent, nationally representative NHANES data allowed us to estimate the 
prevalence (airflow obstruction or self-reported COPD) for the low, medium, and high 
exposure levels for each work exposure. Therefore, we were able to determine that airflow 
obstruction is associated with both self-reported exposures (mineral dust, organic dust, and 
exhaust fumes) and JEM-assigned exposures (mineral dust, organic dust, combined dust, 
diesel exhaust, vapor-gas, sensitizers, and overall exposure). Self-reported COPD is also 
associated with both self-reported exposures (mineral dust, organic dust, exhaust fumes, 
other gases/vapors/fumes, and ever dust and/or fumes) and JEM-assigned exposures 
(mineral dust, organic dust, combined dust, diesel exhaust, vapor-gas, sensitizers, and overall 
exposure).
Halldin et al5 investigated self-reported occupational exposure among ever-employed 
NHANES 2007–2010 participants aged 40–79 years and found significant associations 
between chronic bronchitis and, separately, between emphysema and dust and/or fume 
exposure, dust exposure, and exhaust fume exposure. Although Halldin et al5 did not find 
occupational exposure to be significantly associated with airflow obstruction, we found the 
odds of airflow obstruction were significantly elevated in those reporting organic dust 
exposure and specifically in those with 10–19 years of organic dust exposure compared to 
those not exposed. In our analysis, we included NHANES ever-employed US adults aged 
18–79 years and an additional survey cycle of data (2011–2012) which may explain some of 
the differences in the results of the two studies.
We also found that ≥20 years of exposure to mineral dust, organic dust, or exhaust fumes 
was associated with 44–73% higher odds of airflow obstruction than no exposure. This is 
consistent with Minov et al23 who reported the prevalence of COPD (defined as post-
bronchodilator FEV1/FVC < 0.70) in dusty occupation groups was related to exposure ≥20 
years. Lytras et al9 found 20 years of occupational exposures to biological dusts, gases and 
fumes, and pesticides were associated with increased incidence of COPD (defined as 
FEV1/FVC < LLN post-bronchodilator spirometry). Biological dust is similar to the 
category of organic dust.
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As only a limited number of NHANES participants selected for post-bronchodilator 
spirometry actually performed it, we used pre-bronchodilator spirometry. Alif et al,24 in 
their systematic review and meta-analysis of occupational exposure and COPD (defined as 
FEV1/FVC < 0.70 and/or FEV1/FVC < LLN), reported that four of five studies had used 
pre-bronchodilator spirometry and had found exposure to mineral dust and gases/fumes to be 
associated with increased risk of COPD.
Tables 1–3 present self-reported and JEM-assigned exposures. The exposures captured in 
this study may involve different types of work. For example, combined dust includes mineral 
dust (including silica dust), organic dust, and metal dust from work in construction and 
extraction (including mining dust).25,26 Metal furnace work may involve exposure to silica 
dust where green sand is used toline molds. Metal dust and fume exposure can result from 
welding, grinding, and smelting. Organic dust exposure can result from sawing and sanding 
wood.
Exhaust fumes or diesel exhaust are produced from diesel engines; exposures occur in a 
variety of extraction occupations including drillers and mining workers27 and construction 
occupations including highway maintenance repair and equipment operators.28,29 Vapor-gas 
exposure may occur in roofing, metal plating, metal furnace operations, and welding.
4.1 | Limitations and strengths
The NIOSH COPD-JEM, based on the principles of the Blanc et al7 COPD-JEM, was 
expanded to include additional exposure categories and was not limited to an overall 
exposure level. Although in NHANES occupation was determined by interview, applying 
the NIOSH COPD-JEM may be a less costly and time consuming method of assigning 
occupational exposures than evaluating the full occupational history to derive specific 
exposures. The JEM method is also useful in evaluating occupational exposures when self-
reported data beyond occupation (or longest occupation) are not available.24 The application 
of the JEM method is more resistant to recall bias since exposures are assigned.30,31 Sadhra 
et al32 conducted a systematic review of occupational COPD and JEMs and concluded that 
self-reported occupational exposures may result in overestimates of occupational COPD. 
However, there are also limitations with JEM-assigned exposures which may not capture the 
individual’s unique exposure, resulting in misclassification.
Even a large study such as NHANES has limits. For example, clinical data were not 
available to validate self-reported COPD. Additionally, estimates were not presented for 
some categories of never smokers (Tables 2 and 3) because of RSEs >36%. Potentially 
unreliable RSEs may be due to less airflow obstruction and self-reported COPD among 
never smokers. Furthermore, those that never smoke and are working may be healthier. 
Participants with any airflow obstruction defined by spirometry or self-reported COPD were 
included in the analysis. We did not exclude those with asthma because the type of airflow 
obstruction (eg, asthma, chronic bronchitis, emphysema) among those with spirometry-
defined airflow obstruction was not determined in this study. It is unknown if asthma would 
change the estimates. Main confounders adjusted for included age, gender, race, and 
cigarette use, although potential confounding by other factors cannot be ruled out. However, 
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when Halldin etal analyzed NHANES 2007–2010data, there was no trend in airflow 
obstruction by level of education (an indicator of socioeconomic status).5
A strength is the high quality spirometry data in this recent, nationally representative data set 
with detailed, four-digit Census occupation codes. We were able to apply the NIOSH 
COPD-JEM to detailed occupations. The COPD-JEM was created for use in the US 
population and was used in MESA12 and Kaiser Permanente studies.33
5 | CONCLUSION
Airflow obstruction and self-reported COPD are associated with both self-reported and 
JEM-assigned exposures in a nationally representative study. The detailed occupations added 
to this NHANES data allowed the use of a COPD-JEM for exposure assessment. Results 
from this study use a nationally representative dataset of ever-employed US adults to 
identify occupational exposures with the greatest airflow obstruction burden. The NIOSH 
COPD-JEM may be applicable in other studies.
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